1,183,040 Shares in Xilio Therapeutics, Inc. $XLO Purchased by Empery Asset Management LP

Empery Asset Management LP acquired a new position in Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 1,183,040 shares of the company’s stock, valued at approximately $757,000. Xilio Therapeutics comprises approximately 0.7% of Empery Asset Management LP’s investment portfolio, making the stock its 16th largest holding.

Separately, Squarepoint Ops LLC raised its stake in shares of Xilio Therapeutics by 39.6% during the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after purchasing an additional 93,338 shares in the last quarter. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Stock Performance

Shares of NASDAQ XLO opened at $7.90 on Thursday. The firm has a market cap of $51.98 million, a price-to-earnings ratio of -2.22 and a beta of -0.12. The business’s 50-day simple moving average is $8.25 and its 200-day simple moving average is $8.60. Xilio Therapeutics, Inc. has a 52 week low of $6.47 and a 52 week high of $12.74.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.08. The business had revenue of $12.65 million for the quarter, compared to analyst estimates of $8.52 million. Xilio Therapeutics had a negative return on equity of 151.42% and a negative net margin of 58.52%.

Analysts Set New Price Targets

XLO has been the subject of a number of recent research reports. Wall Street Zen downgraded Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $28.00.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.